Food and Drug Administration
Center for Drug Evaluation and Research

Final Summary Minutes of the Antimicrobial Drugs Advisory Committee Meeting
April 17, 2023

Location: Please note that due to the impact of the COVID-19 pandemic, all meeting participants joined this advisory committee meeting via an online teleconferencing platform.

Topic: The committee discussed new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant's proposed indication is treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex (ABC) in adults.

These summary minutes for the April 17, 2023 meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) of the Food and Drug Administration were approved on June 21, 2023.

I certify that I attended the April 17, 2023 meeting of the AMDAC of the Food and Drug Administration and that these minutes accurately reflect what transpired.

/s/	**/s/**
Takyiah Stevenson, PharmD	Lindsey R. Baden, MD
Acting Designated Federal Officer, AMDAC	Chairperson, AMDAC

Final Summary Minutes of the Meeting of the Antimicrobial Drugs Advisory Committee
April 17, 2023

The Antimicrobial Drugs Advisory Committee, Center for Drug Evaluation and Research, met on April 17, 2023. The meeting presentations were heard, viewed, captioned, and recorded through an online teleconferencing platform. Prior to the meeting, the members and temporary voting members were provided the briefing materials from the FDA and Entasis Therapeutics, Inc. The meeting was called to order by Lindsey R. Baden, MD. The conflict-of-interest statement was read into the record by Takyiah Stevenson, PharmD (Acting Designated Federal Officer). There were approximately 1412 people viewing the meeting. There was a total of six Open Public Hearing (OPH) speaker presentations.

A verbatim transcript will be available, in most instances, at approximately ten to twelve weeks following the meeting date.

Agenda:
The committee discussed new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant's proposed indication is treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex (ABC) in adults.

Attendance:

Antimicrobial Drugs Advisory Committee Members (Voting):
Lindsey R. Baden, MD (Chairperson); Michael D. Green, MD, MPH; W. David Hardy, MD, AAHIVS; Sally A. Hunsberger, PhD; Richard A. Murphy, MD, MPH; Nimish Patel, PharmD, PhD; Federico Perez, MD, MS; George K. Siberry, MD, MPH; Sankar Swaminathan, MD; Roblena E. Walker, PhD (Consumer Representative)

Antimicrobial Drugs Advisory Committee Member Not Present (Voting):
Ighovwerha Ofotokun, MD, MSc

Antimicrobial Advisory Committee Member (Non-Voting):
Richa S. Chandra, MD, MBA (Industry Representative)

Temporary Members (Voting):
Laura C. Block, PharmD (Patient Representative); Joan F. Hilton, ScD, MPH

FDA Participants (Non-Voting):
John Farley, MD, MPH; Adam Sherwat, MD; Peter Kim, MD, MS; Dmitri Iarikov, MD, PhD; Mayurika Ghosh, MD; Karen Qi, PhD; Simone Shurland, PhD; Xiaohui (Tracey) Wei, PhD

Acting Designated Federal Officer (Non-Voting): Takyiah Stevenson, PharmD

Open Public Hearing Speakers Present:
Nicholas Mercuro, PharmD, BCIDP; Alexandre Malek, MD; Robert A. Bonomo, MD; Allison Nazinitsky; Consuelo Relko; Rebecca O'Toole

The agenda was as follows:

Call to Order	**Lindsey R. Baden, MD** Chairperson, AMDAC
Introduction of Committee and Conflict of Interest Statement	**Takyiah Stevenson, PharmD** Acting Designated Federal Officer, AMDAC
FDA Opening Remarks	**Adam Sherwat, MD** Deputy Director Office of Infectious Diseases (OID) Office of New Drugs (OND), CDER, FDA
APPLICANT PRESENTATIONS	**Entasis Therapeutics, Inc.**
Introduction	**Shruta Rege, PhD** Senior Vice President, Head of Regulatory Affairs and Development Operations Entasis Therapeutics
Unmet Need	**David Paterson, MBBS, PhD, FRACP** Professor Saw Swee Hock School of Public Health National University of Singapore
Microbiology and Pharmacology	**Alita Miller, PhD** Senior Vice President, Head of Research Entasis Therapeutics
Efficacy	**David Altarac, MD, MPA** Chief Medical Officer Entasis Therapeutics
Safety	**Drew Lewis, MD, MTM&H, FACP** Vice President, Clinical Development Entasis Therapeutics

Clinical Perspective	**J. Patrik Hornak, MD** Assistant Professor of Medicine Division of Infectious Diseases Assistant Clinical Director, AIDS Education & Training Center University of Texas Medical Branch at Galveston
Concluding Remarks	**Shruta Rege, PhD** Senior Vice President, Head of Regulatory Affairs and Development Operations Entasis Therapeutics
Clarifying Questions	

BREAK

FDA PRESENTATIONS

Efficacy Assessment	**Karen Qi, PhD** Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA
Clinical Safety Assessment	**Mayurika Ghosh, MD** Clinical Reviewer Division of Anti-Infectives (DAI) OID, OND, CDER, FDA
Clinical Microbiology Assessment	**Simone Shurland, PhD** Clinical Microbiology Reviewer DAI, OID, OND, CDER, FDA
Clinical Pharmacology Assessment	**Xiaohui (Tracey) Wei, PhD** Clinical Pharmacology Reviewer Division of Infectious Disease Pharmacology Office of Clinical Pharmacology, CDER, FDA
Clarifying Questions	

LUNCH

OPEN PUBLIC HEARING

Charge to the Committee — **Peter Kim, MD, MS**
Director
DAI, OID, OND, CDER, FDA

Questions to the Committee/Committee Discussion

ADJOURNMENT

Question to the Committee:

1. **VOTE:** Is the overall benefit-risk assessment favorable for the use of sulbactam-durlobactam for the treatment of patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex (ABC) organisms?

    a. If yes, please provide your rationale.
    b. If no, please provide your rationale and describe what additional studies/trials are needed.

    Vote Result: Yes: 12 No: 0 Abstain: 0

    Committee Discussion*: The committee unanimously agreed (12 members) that the overall benefit-risk assessment is favorable for the use of sulbactam-durlobactam for the treatment of patients 18 years or older with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (ABC) organisms. Several members concurred that there is a critical and unmet need for effective antibacterials against highly resistant strains of ABC organisms. The committee agreed that the study demonstrated compelling results for the efficacy of sulbactam-durlobactam in reducing mortality in HABP/VABP caused by ABC but highlighted the limitations of a small safety database. Several members agreed the data demonstrated that sulbactam-durlobactam is a safer alternative to colistin, which is known for its nephrotoxicity, but the committee recommended that post-marketing surveillance be conducted to collect more safety data. Please see the transcript for details of the Committee's discussion.*

The meeting was adjourned at approximately 2:52 p.m. ET on April 17, 2023.